Seres Therapeutics (MCRB) Competitors

$7.92 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$7.93 +0.01 (+0.18%)

As of 05/22/2026 07:21 PM Eastern

MCRB vs. RGNX, NGEN, ELDN, NVCT, and NAGE

Should you buy Seres Therapeutics stock or one of its competitors? MarketBeat compares Seres Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seres Therapeutics include REGENXBIO (RGNX), NervGen Pharma (NGEN), Eledon Pharmaceuticals (ELDN), Nuvectis Pharma (NVCT), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry.

How does Seres Therapeutics compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

REGENXBIO presently has a consensus target price of $23.91, suggesting a potential upside of 276.52%. Seres Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 177.78%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, REGENXBIO had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for REGENXBIO and 1 mentions for Seres Therapeutics. REGENXBIO's average media sentiment score of 0.22 beat Seres Therapeutics' score of 0.00 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seres Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Seres Therapeutics' return on equity of -130.29% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Seres Therapeutics	N/A	-130.29%	-35.35%

REGENXBIO has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Seres Therapeutics has lower revenue, but higher earnings than REGENXBIO. Seres Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	1.93	-$193.88M	-$5.60	N/A
Seres Therapeutics	$790K	97.05	$5.70M	-$5.17	N/A

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

REGENXBIO beats Seres Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to NervGen Pharma?

Seres Therapeutics (NASDAQ:MCRB) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

59.3% of Seres Therapeutics shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, NervGen Pharma had 11 more articles in the media than Seres Therapeutics. MarketBeat recorded 12 mentions for NervGen Pharma and 1 mentions for Seres Therapeutics. NervGen Pharma's average media sentiment score of 0.32 beat Seres Therapeutics' score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seres Therapeutics has higher revenue and earnings than NervGen Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	97.05	$5.70M	-$5.17	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Seres Therapeutics presently has a consensus price target of $22.00, suggesting a potential upside of 177.78%. NervGen Pharma has a consensus price target of $18.00, suggesting a potential upside of 765.38%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

NervGen Pharma's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
NervGen Pharma	N/A	N/A	N/A

Summary

NervGen Pharma beats Seres Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Seres Therapeutics compare to Eledon Pharmaceuticals?

Seres Therapeutics (NASDAQ:MCRB) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.54 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	97.05	$5.70M	-$5.17	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Eledon Pharmaceuticals' return on equity of -116.97% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Seres Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Seres Therapeutics presently has a consensus target price of $22.00, suggesting a potential upside of 177.78%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 148.50%. Given Seres Therapeutics' higher probable upside, research analysts plainly believe Seres Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Seres Therapeutics and Eledon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Seres Therapeutics compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Seres Therapeutics has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Seres Therapeutics	$790K	97.05	$5.70M	-$5.17	N/A

In the previous week, Seres Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 1 mentions for Seres Therapeutics and 0 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.00 beat Seres Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvectis Pharma	Positive
Seres Therapeutics	Neutral

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 30.5% of Nuvectis Pharma shares are held by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Seres Therapeutics' return on equity of -130.29% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Seres Therapeutics	N/A	-130.29%	-35.35%

Nuvectis Pharma currently has a consensus price target of $10.00, suggesting a potential downside of 3.38%. Seres Therapeutics has a consensus price target of $22.00, suggesting a potential upside of 177.78%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvectis Pharma has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Summary

Seres Therapeutics beats Nuvectis Pharma on 8 of the 12 factors compared between the two stocks.

How does Seres Therapeutics compare to Niagen Bioscience?

Seres Therapeutics (NASDAQ:MCRB) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Niagen Bioscience has a net margin of 14.29% compared to Seres Therapeutics' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Niagen Bioscience	14.29%	22.68%	16.23%

Niagen Bioscience has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	97.05	$5.70M	-$5.17	N/A
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43

In the previous week, Niagen Bioscience had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 2 mentions for Niagen Bioscience and 1 mentions for Seres Therapeutics. Niagen Bioscience's average media sentiment score of 1.00 beat Seres Therapeutics' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Seres Therapeutics presently has a consensus target price of $22.00, suggesting a potential upside of 177.78%. Niagen Bioscience has a consensus target price of $14.67, suggesting a potential upside of 300.73%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Niagen Bioscience beats Seres Therapeutics on 14 of the 16 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$76.70M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.53	18.74	21.21	25.65
Price / Sales	97.05	323.98	554.38	86.31
Price / Cash	7.29	125.17	43.49	56.67
Price / Book	2.89	7.09	10.37	7.14
Net Income	$5.70M	$24.45M	$3.57B	$335.98M
7 Day Performance	6.45%	6.38%	6.40%	4.15%
1 Month Performance	-2.22%	2.43%	3.53%	2.54%
1 Year Performance	3.26%	62.98%	34.04%	35.06%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	1.6363 of 5 stars	$7.92 flat	$22.00 +177.8%	+3.3%	$76.70M	$790K	N/A	330
RGNX REGENXBIO	3.06 of 5 stars	$5.65 -1.2%	$23.91 +323.2%	-34.6%	$295.71M	$170.44M	N/A	370
NGEN NervGen Pharma	3.7236 of 5 stars	$3.64 +2.0%	$18.00 +394.5%	N/A	$293.50M	N/A	N/A	N/A	Positive News
ELDN Eledon Pharmaceuticals	1.8839 of 5 stars	$3.58 -5.8%	$9.67 +170.0%	+27.5%	$293.31M	N/A	N/A	10
NVCT Nuvectis Pharma	0.8279 of 5 stars	$10.40 -5.8%	$10.00 -3.8%	+5.3%	$292.85M	N/A	N/A	8	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. RGNX, NGEN, ELDN, NVCT, and NAGE

How does Seres Therapeutics compare to REGENXBIO?

Summary

How does Seres Therapeutics compare to NervGen Pharma?

Summary

How does Seres Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Seres Therapeutics compare to Nuvectis Pharma?

Summary

How does Seres Therapeutics compare to Niagen Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. RGNX, NGEN, ELDN, NVCT, and NAGE

How does Seres Therapeutics compare to REGENXBIO?

Do analysts rate RGNX or MCRB?

Does the media prefer RGNX or MCRB?

Is RGNX or MCRB more profitable?

Which has more volatility & risk, RGNX or MCRB?

Which has higher valuation & earnings, RGNX or MCRB?

Do institutionals & insiders have more ownership in RGNX or MCRB?

Summary

How does Seres Therapeutics compare to NervGen Pharma?

Do institutionals and insiders have more ownership in MCRB or NGEN?

Does the media prefer MCRB or NGEN?

Which has stronger earnings & valuation, MCRB or NGEN?

Do analysts prefer MCRB or NGEN?

Is MCRB or NGEN more profitable?

Summary

How does Seres Therapeutics compare to Eledon Pharmaceuticals?

Does the media refer more to MCRB or ELDN?

Do insiders and institutionals hold more shares of MCRB or ELDN?

Which has better earnings & valuation, MCRB or ELDN?

Is MCRB or ELDN more profitable?

Which has more risk & volatility, MCRB or ELDN?

Do analysts rate MCRB or ELDN?

Summary

How does Seres Therapeutics compare to Nuvectis Pharma?

Which has preferable valuation & earnings, NVCT or MCRB?

Does the media refer more to NVCT or MCRB?

Do insiders & institutionals hold more shares of NVCT or MCRB?

Is NVCT or MCRB more profitable?

Do analysts rate NVCT or MCRB?

Which has more volatility & risk, NVCT or MCRB?

Summary

How does Seres Therapeutics compare to Niagen Bioscience?

Is MCRB or NAGE more profitable?

Which has higher valuation & earnings, MCRB or NAGE?

Does the media favor MCRB or NAGE?

Which has more volatility and risk, MCRB or NAGE?

Do insiders and institutionals have more ownership in MCRB or NAGE?

Do analysts recommend MCRB or NAGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools